ConductScience.org, home

Paper33340331

The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.

Willvonseder B and 14 others. Cancer Immunol Immunother, 2021. Cited by 31 papers, by iCite.

Cite this record

ConductScience Library. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Papers, record 33340331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33340331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
1.64
iCite
Revised in PubMed
2023-02-14
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Willvonseder BBarbara
2Stögbauer FFabian
3Steiger KKatja
4Jesinghaus MMoritz
5Kuhn PHPeer-Hendrik
6Brambs CChristine
7Engel JJutta
8Bronger HHolger
9Schmidt GPGeorg Philipp
10Haller BBernhard
11Weichert WWilko
12Keller GGisela
13Noske AAurelia
14Pfarr NNicole
15Boxberg MMelaniehttps://orcid.org/0000-0001-5989-7922

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biomarkers, TumorMajor topic
Carcinoma, EndometrioidMajor topic
Endometrial NeoplasmsMajor topic
Lymphocytes, Tumor-InfiltratingMajor topic
Microsatellite InstabilityMajor topic
MutationMajor topic
Tumor MicroenvironmentMajor topic
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Middle Aged
Prognosis
Retrospective Studies
Survival Rate

Source PubMed

Download CSV of topics

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130620402Cancer statistics, 2019.CA Cancer J Clin2019https://conductscience.org/library/papers/30620402PubMed
230550484Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.Int J Gynecol Pathol2019https://conductscience.org/library/papers/30550484PubMed
323868500Immune system: a double-edged sword in cancer.Inflamm Res2013https://conductscience.org/library/papers/23868500PubMed
426172027A clinically applicable molecular-based classification for endometrial cancers.Br J Cancer2015https://conductscience.org/library/papers/26172027PubMed
528061006Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Cancer2017https://conductscience.org/library/papers/28061006PubMed
627006490Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.Clin Cancer Res2016https://conductscience.org/library/papers/27006490PubMed
729344951The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.J Pathol2018https://conductscience.org/library/papers/29344951PubMed
827999680New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.Gynecol Oncol Res Pract2016https://conductscience.org/library/papers/27999680PubMed
928102259Elements of cancer immunity and the cancer-immune set point.Nature2017https://conductscience.org/library/papers/28102259PubMed
1026181000Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.JAMA Oncol2015https://conductscience.org/library/papers/26181000PubMed
1125977340Classifying Cancers Based on T-cell Infiltration and PD-L1.Cancer Res2015https://conductscience.org/library/papers/25977340PubMed
1226989092Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.Int Immunol2016https://conductscience.org/library/papers/26989092PubMed
1324925396T cell subpopulations.Chem Immunol Allergy2014https://conductscience.org/library/papers/24925396PubMed
1425275055Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma.Anticancer Res2014https://conductscience.org/library/papers/25275055PubMed
1521897268Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer.Int J Gynecol Cancer2011https://conductscience.org/library/papers/21897268PubMed
1630401949T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.Mod Pathol2019https://conductscience.org/library/papers/30401949PubMed
1730291344Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.Mod Pathol2019https://conductscience.org/library/papers/30291344PubMed
1828344870Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.Oncoimmunology2017https://conductscience.org/library/papers/28344870PubMed
1929464025Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.Oncotarget2018https://conductscience.org/library/papers/29464025PubMed
2030530592Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma.J Immunol2019https://conductscience.org/library/papers/30530592PubMed

See all 29 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
42936408Functional single-cell omics in gynecological cancers immunotherapy: from heterogeneity dissection to clinical translation.Front Immunol2026https://conductscience.org/library/papers/42936408PubMed
41891942ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities.J Pathol Clin Res2026https://conductscience.org/library/papers/41891942PubMed
41528614Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma.Discov Oncol2026https://conductscience.org/library/papers/41528614PubMed
41476451Estrogen receptor α expression in tumor-infiltrating lymphocytes from patients with endometrial cancer.Oncol Lett2026https://conductscience.org/library/papers/41476451PubMed
41472355Diagnostic Challenges and Clinical Implications of Microsatellite Instability/Mismatch Repair Deficiency in Solid Tumors.Cancer Res Treat2026https://conductscience.org/library/papers/41472355PubMed
41394227Analysis of the Clinicopathological Characteristics of Different Molecular Subtypes in Endometrial Cancer: A Retrospective Single Center Study.Int J Gen Med2025https://conductscience.org/library/papers/41394227PubMed
41312167Navigating tumour microenvironment in endometrial carcinoma: a comprehensive review integrating immunohistochemistry, single-cell RNA-sequencing and spatial transcriptomics.Front Oncol2025https://conductscience.org/library/papers/41312167PubMed
40940815Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications.Cells2025https://conductscience.org/library/papers/40940815PubMed
40894206Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database.Front Pharmacol2025https://conductscience.org/library/papers/40894206PubMed
40321963The prognostic implication of polymerase epsilon-mutated endometrial cancer.Tzu Chi Med J2025https://conductscience.org/library/papers/40321963PubMed
39751650Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification.Cancer Immunol Immunother2025https://conductscience.org/library/papers/39751650PubMed
39730507A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer.Sci Rep2024https://conductscience.org/library/papers/39730507PubMed
38585471Assessment of Immune Status in Patients with Mismatch Repair Deficiency Endometrial Cancer.J Inflamm Res2024https://conductscience.org/library/papers/38585471PubMed
38305309TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.Recent Pat Anticancer Drug Discov2025https://conductscience.org/library/papers/38305309PubMed
37568665Tumor Immune Microenvironment in Gynecologic Cancers.Cancers (Basel)2023https://conductscience.org/library/papers/37568665PubMed
37568650Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients.Cancers (Basel)2023https://conductscience.org/library/papers/37568650PubMed
37035329Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma.Front Med (Lausanne)2023https://conductscience.org/library/papers/37035329PubMed
36937436ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer.Front Oncol2023https://conductscience.org/library/papers/36937436PubMed
36675532Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer.J Clin Med2023https://conductscience.org/library/papers/36675532PubMed
36612250Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).Cancers (Basel)2022https://conductscience.org/library/papers/36612250PubMed

See all 28 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33340331

GET https://conductscience.org/api/papers/v1/33340331/references?page=2